Founder, The Haul Company
Founder, Young Inventors
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Medical College of Wisconsin director of research commercialization
Founder and Managing Director of DEV
Managing Director, D.E. Shaw and Co., L.P.
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Co-Founder, Sakti3
The FDA today has made Zolgensma, a Novartis treatment for the rare genetic disease spinal muscular atrophy, the second approved gene therapy in the US.
The news marks a milestone for patients with SMA, who have only one other approved medicine... Read more »
Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma, a Novartis (NYSE: NVS) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio,... Read more »
[Corrected 5/21/19, 11:04 am. See below.] Sebastian Thrun first made his mark on autonomous vehicle development at the dawn of that industry, when he led a Stanford team whose robot car Stanley won the $2 million DARPA Grand Challenge... Read more »
Yet another new biotech company has been founded in San Diego by serial entrepreneur Mike Grey and other alumni of rare disease startup Lumena Pharmaceuticals.
Reneo Pharmaceuticals, which has offices in San Diego and in the UK, announced Monday it has... Read more »
Let’s catch up with the latest life sciences news in San Diego.
— Cybersecurity company MedCrypt, which makes software to protect medical devices, raised a $5.3 million Series A funding round.
The company says it will use the new funds to... Read more »
Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But... Read more »
The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break companies whose drugs are under the microscope. That’s what makes... Read more »
BioClarity, which sells plant-based skincare products to online shoppers, announced Wednesday that it has raised a $13 million investment round.
The San Diego-based company is part of Adigica Health, an e-commerce company founded in 2016 to develop and market direct-to-consumer healthcare... Read more »
The finalists in the Big Idea category of the Xconomy Awards San Diego are pursuing ambitious goals in pursuit of better ways of improving health. Their approaches range, from a new way to deliver insulin to patients with Type 1 diabetes... Read more »
Austin—MassChallenge has picked the 74 early-stage companies that will eventually compete for a portion of $500,000 in cash as a part of its Austin accelerator program. They’re startups that are developing products in a wide range of sectors, including life... Read more »
San Diego has had plenty of businesses go public in recent years, but most have been life sciences companies.
Now software startup Tealium, which has about 215 employees at its San Diego headquarters, announced Wednesday it has added $55 million in... Read more »
CrowdStrike, the cybersecurity company that identified the two Russian government-linked hacker groups that invaded the Democratic National Committee (DNC)’s network during the 2016 presidential campaign, filed publicly for an initial public offering on Tuesday.
Sunnyvale, CA-based CrowdStrike sells cloud-based security... Read more »
The Xconomy Awards categories weren’t enough to capture the full diversity of the San Diego life science community. So we at Xconomy created X of the Year for people who are so unique they needed their own categories. Read on for... Read more »
With Uber’s long-awaited IPO, Facebook’s mounting controversies, and ongoing debates over drug pricing and safety issues, come a great responsibility. A big story in the innovation community now is about the ethics and regulation of tech and life sciences. What are... Read more »
The market for drugs for rare or “orphan” diseases continues to grow. An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12 percent a year between now and 2024, when they will account for an estimated 20... Read more »
[Updated 5/10/19, 5 pm ET. See below.] Ride-hailing giant Uber secured $8.1 billion in new capital late Thursday as it priced an initial public offering that set its market capitalization at $82.4 billion, according to calculations by The... Read more »
It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least... Read more »
The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy,... Read more »
The finalists in the Startup category of San Diego’s Xconomy Awards (and other categories) show how much data security and privacy have become not just top public concerns but also the priorities of a growing number of companies. Other Startup finalists... Read more »
[Updated 5/6/19, 9:20 am ET. See below.] A year ago, there were no FDA-approved medicines available for US patients with the debilitating rare genetic disease transthyretin amyloidosis (ATTR). Things have changed fast, however: With the FDA’s decision to approve... Read more »
Danish pharma firm Lundbeck has agreed to acquire Abide Therapeutics for $250 million upfront.
The La Jolla-CA-based company, spun out of research from The Scripps Research Institute (TSRI), is developing drugs to treat diseases of the central nervous system, among them... Read more »
America continues to suffer from healthcare headaches. Our convoluted private-public insurance system was under scrutiny this week from Democrats, holding a “Medicare for All” hearing in the House, and from Republicans, as several GOP-led states and the Trump administration asked... Read more »
Sponsored · Whitepaper
Read Now
Xiltrix
Sponsored · Whitepaper
Keep easily accessible, historical records to aid in root cause analysis for deviations
XiltriX
From Our Editors · Special Report
Facing an Uncertain Future
Xconomy
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation
Founder and CEO, eFFECTOR Therapeutics
Founder, Science Applications International Corp. Inc.
Former President and CEO, Regulus Therapeutics
Founding Director of Calit2
CEO and Co-Founder, Receptos
Professor, Gene Expression Laboratory, Salk Institute
Managing Director, DaggerBoard Advisors
Founding Managing Partner, Forward Ventures
Professor, Laboratory of Genetics, Salk Institute
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
